Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
- Patients using GLP-1s with the Virtual Care Suite showed a 6.1% increase in lean body mass and 6.4% increase in muscle mass
- Combination therapy of Allurion Balloon with semaglutide achieved 21.2% body weight reduction, comparable to bariatric surgery outcomes
- The Allurion Program without GLP-1s demonstrated 12.4% weight reduction and 9.8% muscle mass increase in 2,000 patients
The studies suggest that Allurion's AI-driven behavioral support may help maintain muscle mass during GLP-1 therapy, while combination treatments could offer alternatives to bariatric surgery for severe obesity cases.
Allurion Technologies (NYSE: ALUR), a company focused on obesity treatment, has scheduled its first quarter 2025 financial results announcement for May 14, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.
Participants can join via phone by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone at (800) 770-2030 using Access Code 1905455, and the archived webcast will remain available on the company's website.
Allurion Technologies (NYSE: ALUR) has announced the postponement of its Special Meeting of Stockholders from April 4, 2025, to Thursday, April 10, 2025, at 12:00 p.m. (Eastern Time). The virtual meeting will be held via live audio webcast.
The postponement aims to allow additional time for proxy solicitation and provide stockholders more time to vote. The record date remains unchanged at March 14, 2025. Previously cast votes will remain valid unless stockholders choose to change or revoke them.
The Company's Board of Directors unanimously recommends voting FOR the proposals outlined in the Definitive Proxy Statement filed on March 24, 2025. Stockholders can access detailed information and voting instructions through the SEC website or Allurion's investor relations page.
Allurion Technologies (NYSE: ALUR) reported its Q4 and full-year 2024 financial results. Q4 revenue was $5.6 million with full-year revenue reaching $32.1 million. The company faced challenges with Q4 gross profit at $2.5 million (45% margin), down from $6.4 million (78% margin) in Q4 2023.
Key developments include:
- Resumed sales in France on February 12, 2025
- Positive topline results from AUDACITY FDA trial
- Initial data showing promising results combining Allurion Program with low-dose GLP-1s
- Launch of next-generation Allurion Balloon with smaller capsule size
The company reduced Q4 2024 operating expenses by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges. For 2025, Allurion projects revenue of approximately $30 million and plans to cut operating expenses by roughly 50% compared to 2024.
Allurion Technologies (NYSE: ALUR) has revealed promising initial results from combining the Allurion Program with low-dose GLP-1 therapy. The study involved 52 patients who received the Allurion Balloon and started on 0.25mg semaglutide, gradually increased to 1.0mg over 6 months.
Key findings after 8 months include:
- 20.3% average total body weight loss
- 15% increase in lean body mass (from 59.6% to 68.5%)
- 100% patient adherence to GLP-1 medication
This combination approach addresses common challenges with standalone GLP-1 therapy, which typically shows 40% reduction in lean mass and high discontinuation rates (30% in first month, 58% before reaching meaningful health benefits). The study used lower semaglutide doses (max 1.0mg) compared to typical 2.4mg dosing, resulting in fewer side effects and better adherence.
Allurion Technologies (NYSE: ALUR), an anti-obesity focused company, has scheduled its fourth quarter 2024 financial results announcement for March 26, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.
Investors can access the conference call via phone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone using Access Code 1905455 and through the archived webcast on the company's IR website.
Allurion Technologies (NYSE: ALUR) has received two new U.S. patent notifications from the USPTO for its next-generation weight loss device. The patents, scheduled to issue on March 11, 2025, cover an enhanced valve for balloon filling and an innovative balloon opening mechanism, providing protection through April 2043.
The company's patent portfolio now includes 22 U.S. patents and 64 global patents. The Allurion Program combines their swallowable, procedure-less gastric balloon with the Allurion Virtual Care Suite, featuring a Mobile App, Connected Scale, and Iris AI Platform for healthcare providers.
Clinical results show patients typically lose 10-15% of their total body weight, with some studies demonstrating increased muscle mass. The company plans to conduct new clinical trials combining the Allurion Balloon with GLP-1 therapy.
Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has announced its participation in two major upcoming investor conferences. Dr. Shantanu Gaur, Founder and CEO, will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, where he will also conduct one-on-one investor meetings.
Additionally, Dr. Gaur will host individual investor meetings at the 37th Annual Roth Conference in Dana Point, California, from March 16-18, 2025. Investors can access the presentation webcast through the Events & Presentations section of Allurion's investor relations website.
Allurion Technologies (NYSE: ALUR) has successfully closed its previously announced financing round, raising approximately $6.1 million through multiple transactions. The company completed a registered direct offering of 900,000 common stock shares at $5.23 per share, along with warrants for 1,800,000 additional shares. Additionally, a concurrent private placement with Leavitt Equity Partners included 267,686 shares and warrants for 535,372 shares at the same price.
The warrants have an exercise price of $5.23 per share and will become exercisable immediately following stockholder approval, with a five-year expiration term. Roth Capital Partners served as the exclusive placement agent for both transactions. The company plans to use the proceeds to fund clinical trials exploring the combination of the Allurion Balloon with GLP-1 therapy, focusing on muscle mass and long-term GLP-1 adherence, as well as for working capital and general corporate purposes.
Allurion Technologies (NYSE: ALUR) has announced a financing deal to raise approximately $6.1 million in gross proceeds through a combination of offerings. The company will sell 900,000 shares of common stock at $5.23 per share in a registered direct offering and issue warrants for 1,800,000 additional shares in a concurrent private placement.
Additionally, the company entered into a subscription agreement with Leavitt Equity Partners for 267,686 shares and warrants for 535,372 shares at the same price point. The warrants have an exercise price of $5.23 per share and will be exercisable upon stockholder approval, expiring five years after approval.
The proceeds will fund Allurion's clinical pipeline testing the combined effects of the Allurion Balloon and GLP-1 therapy on muscle mass and long-term GLP-1 adherence, working capital, and general corporate purposes. The closing is expected around February 20, 2025.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
